技术指标
指标
数值
方向
MACD(12,26,9)
0.051
买入
RSI(14)
48.824
中性
STOCH(KDJ)(9,3,3)
26.025
卖出
ATR(14)
1.404
低波动
CCI(14)
-86.493
中性
Williams %R
97.710
超卖
TRIX(12,20)
2.832
卖出
StochRSI(14)
0.000
卖出
搜索
NextCure Inc
NXTC添加自选
4.145USD
-0.885-17.59%
收盘 07-31 16:00（美东）报价延迟15分钟
14.95M总市值
亏损市盈率 TTM
关键数据
4.910今开
5.080最高
385.71K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
10.69%换手率
5.030昨收
4.100最低
1.31M成交额
亏损市盈率静
0.56市净率
0.00%股息率 TTM
-104.01%ROA
15.74052周最高
0.68量比
-55.65M净利润
3.61M总股本
-16.8133每股收益TTM
1.34Beta
-132.40%ROE
4.60052周最低
19.48%振幅
--毛利率
14.95M总市值
20.34回报/风险
8.24%风险率
TradingKey NextCure Inc股票评分
单位: USD 更新时间: 2026-07-31操作建议
NextCure Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名88/385位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价17.50。中期看，股价处于下降通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
NextCure Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
NextCure Inc亮点
亮点风险
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
估值高估
公司最新PE估值-0.25，处于3年历史高位
机构加仓
最新机构持股1.75M股，环比增加10.95%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
活跃度增加
近期活跃度增加，过去20天平均换手率18.95
分析师目标
根据
2
位分析师
买入
评级
17.500
目标均价
+248.61%
涨幅空间
NextCure Inc新闻
即将为您带来更多新闻，敬请期待。。。
收益预测
分析师评级
根据
2
位分析师
买入
评级
17.500
目标均价
+248.61%
涨幅空间
强力买入
买入
持有
卖出
强力卖出
同行比较
496
总数
6
中位数
7
平均值
公司名称
评级分布
分析师数
NextCure Inc
NXTC
2
百济神州
ONC
27
艾昆纬
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
技术指标
移动平均线
指标
数值
方向
MA5
4.947
卖出
MA10
4.807
卖出
MA20
4.261
卖出
MA50
3.805
买入
MA100
7.270
卖出
MA200
9.500
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NextCure Inc简介
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
公司代码NXTC
公司NextCure Inc
CEORichman (Michael S)
网址https://www.nextcure.com/
公司股东
相关品种
热门品种
常见问题
NextCure Inc(NXTC)的当前股价是多少？
NextCure Inc(NXTC)的当前股价是 4.10。
NextCure Inc的股票代码是什么？
NextCure Inc的股票代码是NXTC。
NextCure Inc股票的52周最高点是多少？
NextCure Inc股票的52周最高点是15.74。
NextCure Inc股票的52周最低点是多少？
NextCure Inc股票的52周最低点是4.60。
NextCure Inc的市值是多少？
NextCure Inc的市值是14.79M。
现在NextCure Inc(NXTC)的股票是买入、持有还是卖出？
根据分析师评级，NextCure Inc(NXTC)的总体评级为买入，目标价格为17.50。
NextCure Inc(NXTC)股票的每股收益（EPS TTM）是多少
NextCure Inc(NXTC)股票的每股收益（EPS TTM）是-19.65。